Rodica Anghel

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial

Christoph Zielinski, István Láng, Moshe Inbar et al. · The Lancet Oncology · 2016 · 58 citations

Medicine, Oncology, Pharmacology +12

Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial

Kathleen M. Mullane, Vicki A. Morrison, Luis H. Camacho et al. · The Lancet Infectious Diseases · 2019 · 36 citations

Veterinary Medicine, Immunology, Infectious Diseases +14

Selecting first-line bevacizumab-containing therapy for advanced breast cancer: TURANDOT risk factor analyses

Thomas Brodowicz, István Láng, Zsuzsanna Kahán et al. · British Journal of Cancer · 2014 · 30 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Predictive role of hand–foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer

Christoph Zielinski, István Láng, S. Beslija et al. · British Journal of Cancer · 2015 · 25 citations · Full text

Medicine, Oncology, Pharmacology +17

Clinical, histological and therapeutical aspects in the management of uterine and extrauterine stromal sarcomas: Case reports

Laura Rebegea, Dorel Firescu, Rodica Anghel et al. · Experimental and Therapeutic Medicine · 2021 · 13 citations · Full text

Medicine, Oncology, Surgery +10